Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma

References

1. 1.↵
   1. Miranda-Filho A,
   2. Piñeros M,
   3. Znaor A,
   4. Marcos-Gragera R,
   5. Steliarova-Foucher E,
   6. Bray F.

   Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control 2019; 30: 489-499.

   OpenUrl
2. 2.↵
   1. Zhou L,
   2. Yu Q,
   3. Wei G,
   4. Wang L,
   5. Huang Y,
   6. Hu K, et al.

   Measuring the global, regional, and national burden of multiple myeloma from 1990-2019. BMC Cancer 2021; 21: 606.
3. 3.↵
   1. Cavo M,
   2. Rajkumar SV,
   3. Palumbo A,
   4. Moreau P,
   5. Orlowski R,
   6. Bladé J, et al.

   International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063-6073.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Baertsch MA,
   2. Kriegsmann K,
   3. Pavel P,
   4. Bruckner T,
   5. Hundemer M,
   6. Kriegsmann M, et al.

   Platelet count before peripheral blood stem cell mobilization is associated with the need for plerixafor but not with the collection result. Transfus Med Hemother 2018; 45: 24-31.

   OpenUrl
5. 5.↵
   1. Wuchter P,
   2. Ran D,
   3. Bruckner T,
   4. Schmitt T,
   5. Witzens-Harig M,
   6. Neben K, et al.

   Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-499.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Attolico I,
   2. Pavone V,
   3. Ostuni A,
   4. Rossini B,
   5. Musso M,
   6. Crescimanno A, et al.

   Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012; 18: 241-249.

   OpenUrlPubMedWeb of Science
7. 7.↵
   1. Mohty M,
   2. Hübel K,
   3. Kröger N,
   4. Aljurf M,
   5. Apperley J,
   6. Basak GW, et al.

   Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014; 49: 865-872.

   OpenUrl
8. 8.↵
   1. Sancho JM,
   2. Morgades M,
   3. Grifols JR,
   4. Juncà J,
   5. Guardia R,
   6. Vives S, et al.

   Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy 2012; 14: 823-829.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Micallef I,
   2. Ansell SM,
   3. Buadi FK,
   4. Dingli D,
   5. Dispenzieri A,
   6. Gastineau DA, et al.

   A risk adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. Blood 2009; 114: 3211.

   OpenUrl
10. 10.↵
    1. D’Addio A,
    2. Curti A,
    3. Worel N,
    4. Douglas K,
    5. Motta MR,
    6. Rizzi S, et al.

    The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-363.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Milone G,
    2. Martino M,
    3. Spadaro A,
    4. Leotta S,
    5. Di Marco A,
    6. Scalzulli P, et al.

    Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2014; 164: 113-123.

    OpenUrlPubMed
12. 12.↵
    1. Costa LJ,
    2. Alexander ET,
    3. Hogan KR,
    4. Schaub C,
    5. Fouts TV,
    6. Stuart RK.

    Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-69.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Sinha S,
    2. Gastineau D,
    3. Micallef I,
    4. Hogan W,
    5. Ansell S,
    6. Buadi F, et al.

    Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011; 46: 943-949.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Horwitz ME,
    2. Chute JP,
    3. Gasparetto C,
    4. Long GD,
    5. McDonald C,
    6. Morris A, et al.

    Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant 2012; 47: 1051-1055.

    OpenUrlPubMed
15. 15.↵
    1. Pusic I,
    2. Jiang SY,
    3. Landua S,
    4. Uy GL,
    5. Rettig MP,
    6. Cashen AF, et al.

    Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.

    OpenUrlCrossRefPubMedWeb of Science